MT is a euro 50 M closed-end venture capital fund dedicated to investments in unlisted innovative, early-stage companies.
Matignon Technologies is a euro 50 M closed-end venture capital fund dedicated to investments in unlisted innovative, early-stage companies specialized in high technologies with strong growth potential. The Fund invests as a minority shareholder with a stake comprised between euro 0.5 M and 3.0 M euro. Subscriptions were closed in September 2000 and the Fund has a lifespan of six years.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 21, 2010
Arterial Remodeling Technologies
|
Series Unknown | $8.50M | Biotechnology | — |
Jul 19, 2010
Gentis
|
Series Unknown | $548.26K | Biotechnology | — |
May 5, 2010
Nanobiotix
|
Series C | €7M | Biotechnology | — |
Oct 7, 2008
Orteq
|
Series B | £8M | Biotechnology | Yes |
Nov 12, 2007
Arterial Remodeling Technologies
|
Series Unknown | €5.50M | Biotechnology | Yes |
Matignon Technologies has had 2 exits. Matignon Technologies most notable exits include Nanobiotix , Alveolus
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Dec 10, 2020 | Nanobiotix | IPO | Biotechnology | Detail |
Feb 19, 2009 | Alveolus | M&A | Medical | Detail |